A Humira biosimilar, produced by drug maker Sandoz, has been given the green light from the US Food and Drug Administration (FDA). Sandoz, a division of Novartis, confirmed that the FDA granted ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

A decade ago, more than 63% of the pharmaceutical giant's revenue was tied up in one drug -- Humira. Granted, it was the ...

A blockbuster drug is a best-selling medication earning over $1 billion annually. Learn about them and how they revolutionize ...

Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market.

Cardinal Health's analysis shows biosimilars are projected to strengthen cost savings and provider confidence across the healthcare ecosystem, with oncology rising in adoption and accessibility gains.

The expansion is expected to create 300 new jobs, including positions for engineers, scientists, manufacturing operators and lab technicians.

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Michael Boyle is an experienced financial professional with more than 10 years working with ...

Well, good morning, everybody, and thank you once again for joining us for the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the biotech team, and it's a great pleasure to moderate ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

A new report paints a stark picture of how a subset of large healthcare providers are drawing the lion’s share of 340B savings within a single state.  | A Minnesota analysis of providers' reported ...